Furthermore, the PD-1-blocking antibody (CT-011, pidilizumab) used to enhance anti-myeloma cytotoxicity responses by NK cells in that report was subsequently found to primarily target the Notch2 ligand, Delta-like 1 (DLL1) [47,48]. This evidence concerns the gene NOTCH2 and plasma cell myeloma.